Fig. 6: Therapeutic efficacy of UHHTN/DOX nanorobots in the treatment of TNBC spinal metastasis.
a Timeline of different treatments and measurements in mice with TNBC spinal metastasis. b Survival curves of nude mice with TNBC spinal metastasis during 20 days treatment at a DOX dosage of 5 mg kg−1 once every four days. c Distribution of UHHTN/DOX/Cy5.5 nanorobots (Dose, 5 mg kg−1) at different time points in isolated spinal tumors, heart, liver, spleen, lung, and kidney. d Representative bioluminescence images of different groups of surviving nude mice with TNBC spinal metastasis recorded at multiple time points after receiving 20 days treatments at a DOX dosage of 5 mg kg−1 once every four days. e Fluorescence analysis of regions of interest for TNBC spinal tumors on bioluminescence imaging at multiple time points after receiving 20 days. Data are presented as the mean ± s.d. Statistical analysis was performed by one-way ANOVA with Tukey’s post hoc test. (n = 5 mice per group; **P < 0.05, ***P < 0.001, ****P < 0.0001). f Tumor weight and (g) volume in nude mice with TNBC spinal metastasis after different 20 days treatments at a DOX dosage of 5 mg kg−1 once every four days. Data are presented as the mean ± s.d. Statistical analysis was performed by two-tailed Student’s t test. (n = 5 mice per group; **P < 0.05, ***P < 0.001, ****P < 0.0001). h Gross T2 MRI and i gross CT imaging of spines (dotted outline) in nude mice 20 days after treatment in different groups at a DOX dosage of 5 mg kg−1 once every four days. j MicroCT bone parameters analysis of bone density and k bone volume/tissue volume ratio at spinal tumor lesions in different treatment groups after 20 days therapy. Data are presented as the mean ± s.d. Statistical analysis was performed by two-tailed Student’s t test. (n = 5 mice per group; **P < 0.05, ***P < 0.001, ****P < 0.0001). Source data for the figure are provided within the Source Data file.
